Terminated PHASE4 INTERVENTIONAL 1-arm NCT00944216

Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study

Sponsor: PreCision Dermatology, Inc.

Updated 7 times since 2017 Last updated: Feb 3, 2022 Started: Jun 30, 2009 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

terminated due to administrative reasons.

Listed as NCT00944216, this PHASE4 trial focuses on Keratosis Pilaris and remains terminated or withdrawn. Sponsored by PreCision Dermatology, Inc., it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Feb 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Mar 2022 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Mar 2022 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PreCision Dermatology, Inc.
Wright State University

Data source: Wright State University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dayton, United States